Interests declared, by advisory body
| Advisory body | Total no. of declarations | No. (%) of declarations; type of interest | ||||
|---|---|---|---|---|---|---|
| Direct financial interest | Indirect financial interest | Direct or indirect financial interest | Intellectual interest | Other interest | ||
| Oncology therapies SAC | 21 | 3 (14.3) | 18 (85.7) | 18 (85.7) | 16 (76.2) | 2 (9.5) |
| Pharmaceutical sciences and clinical pharmacology SAC | 13 | 4 (30.8) | 9 (69.2) | 10 (76.9) | 12 (92.3) | 0 (0) |
| Respiratory and allergy therapies SAC | 19 | 3 (15.8) | 14 (73.7) | 14 (73.7) | 16 (84.2) | 0 (0) |
| Anti-infective therapies SAP | 6 | 1 (16.7) | 2 (33.3) | 2 (33.3) | 6 (100) | 0 (0) |
| Bioequivalence requirements for gender-specific drug products SAP | 7 | 0 (0) | 4 (57.1) | 4 (57.1) | 6 (85.7) | 0 (0) |
| Bioequivalence requirements for modified-release dosage forms SAP | 6 | 0 (0) | 5 (83.3) | 5 (83.3) | 5 (83.3) | 0 (0) |
| Diclectin SAP | 4 | 0 (0) | 1 (25.0) | 1 (25.0) | 1 (25.0) | 0 (0) |
| Opioid analgesic abuse SAP | 6 | 1 (16.7) | 4 (66.7) | 4 (66.7) | 4 (66.7) | 0 (0) |
| Opioid use and contraindications SAP | 6 | 0 (0) | 1 (16.7) | 1 (16.7) | 6 (100) | 2 (33.3) |
| Opioids SAP | 6 | 0 (0) | 2 (33.3) | 2 (33.3) | 6 (100) | 2 (33.3) |
| Isotretinoin risk management SAP | 5 | 0 (0) | 2 (40.0) | 2 (40.0) | 3 (60.0) | 0 (0) |
| Total | 99 | 12 | 62 | 63 | 81 | 6 |
Note: SAC = special advisory committee, SAP = special advisory panel.